FDA pulls back oversight of AI clinical decision support and wearables

The FDA will exercise enforcement discretion for clinical decision support tools that give a single reviewable recommendation, and widened its wellness carve-out for consumer wearables. Enforcement of the new documentation regime begins June 30, 2026.

Why it matters

The change narrows what counts as a regulated device. Tools that surface a single, reviewable recommendation now largely fall outside active oversight.

That is not deregulation of risk, only of review. The risk still lives at the point of care, and the responsibility for catching it moves closer to the clinician.

What to watch

Whether health systems build their own evaluation and monitoring in the space the FDA vacated, or simply trust vendor claims.